![Poseida Therapeutics, Inc. logo](/logos/PSTX.webp)
Poseida Therapeutics, Inc.
NASDAQ:PSTX
Overview | Financials
Company Name | Poseida Therapeutics, Inc. |
Symbol | PSTX |
Currency | USD |
Price | 2.74 |
Market Cap | 266,146,886 |
Dividend Yield | 0% |
52-week-range | 1.83 - 4.27 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark J. Gergen J.D. |
Website | https://www.poseida.com |
An error occurred while fetching data.
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD